Macular Degeneration (AMD): Symptoms, Red Flags & Specialist Referral

Age-related macular degeneration (AMD) is a progressive degenerative disease of the macula—the central retina responsible for high-acuity, straight-ahead vision. Early disease reflects accumulation of extracellular deposits (drusen) and dysfunction of the retinal pigment epithelium (RPE); advanced disease splits into two late phenotypes: neovascular (“wet”) AMD with choroidal neovascularisation (CNV) and exudation, and atrophic (“dry”) late disease with geographic atrophy (GA) of the RPE and outer retina. AMD is a leading cause of irreversible central vision loss in high-income settings among adults over 50; peripheral vision is typically preserved, so patients notice reading difficulty, face recognition loss, and trouble with fine near tasks before they notice “curtain” field loss.

Pathophysiology centres on chronic complement dysregulation, oxidative stress and impaired waste clearance between the RPE and Bruch’s membrane. In wet AMD, up-regulated vascular endothelial growth factor (VEGF) drives fragile new vessels that leak fluid and blood under or into the retina. Wet AMD is less common than dry AMD but often steals vision faster without intravitreal anti-VEGF therapy. Clinic and ward nurses most often meet AMD patients around treatment visits, systemic risk-factor optimisation, or when visual symptoms overlap with vascular and metabolic comorbidity (diabetes mellitus type 2, dyslipidaemia, obesity) and need coordinated referral.

Alignment between optometrist, ophthalmology and primary-care records improves safety: every note should name the phenotype (dry versus wet), the high-risk feature (soft drusen, pigmentary change, subretinal fluid), and the next surveillance interval. Nurses can reinforce that mild drusen alone may need only yearly review, whereas intermediate AMD or any exudative change shortens that interval sharply.

↔On a small screen, swipe or scroll sideways to see the full table.

OCT (optical coherence tomography) has become the non-negotiable structural test: it tracks retinal thickness, subretinal fluid, and intraretinal cystoid fluid—changes that often predate the patient’s subjective report. When you receive a discharge letter listing “disease activity,” it usually refers to fluid on OCT rather than symptoms alone.

Symptoms track stage. Early dry disease is often asymptomatic despite fundus changes. Intermediate dry AMD may produce mild blurred vision, need for brighter light for reading, or subtle vision changes that patients dismiss as cataract until examination stratifies risk.

• Metamorphopsia (straight lines appearing bent or missing) is a classic cue to late AMD—urgent same-day ophthalmology.
• Central loss of vision or a growing central scotoma maps to GA or macular scarring after chronic exudation.
• Rapid onset central blur with new floaters or a “shower” of vitreous debris should also trigger retinal detachment precautions—not every patient with floaters has AMD, but combined symptoms need triage safety-netting.
• Wet AMD can present asymmetrically; ask about recognition of faces, medication label reading, and on-road hazard perception—not only Snellen letters.
• Patients with diabetic retinopathy may attribute AMD symptoms to diabetes alone; insist on structured eye surveillance for both conditions.

AMD is multifactorial. Non-modifiable risks include advancing age, female sex in some cohorts, and family history. Modifiable contributors strongly supported in reviews and meta-analyses include cigarette smoking, hypertension, and broader cardiovascular risk clustering; serum lipids show inconsistent associations in pooled analyses but still merit optimisation because they track with overall vascular health.

• Smoking cessation is the single highest-yield behaviour change—document pack-years and offer cessation referral at every contact.
• Encourage blood pressure and glucose control; track HbA1c in diabetes and align with retinal screening intervals.
• Lipid panels help cardiovascular risk review even when AMD linkage is debated.
• Nutrient patterns (leafy greens, oily fish) and physical activity are reasonable adjuncts; AREDS2 supplements are disease-stage specific—avoid implying they prevent AMD in everyone.
• Stroke and systemic vascular disease should prompt you to verify eye follow-up because shared risk pathways cluster.

Chronic cataract can flatten contrast sensitivity and exaggerate AMD symptoms—sequence surgery only after retina clearance, but do not let cataract assumption delay OCT if wet change is plausible.

Clinical assessment uses monocular best-corrected acuity, Amsler grid testing where available, and systematic symptom enquiry. Fundus examination after dilation remains foundational—look for drusen calibre, pigmentary disturbance, subretinal haemorrhage, or PED.

Imaging: macular OCT is standard for fluid mapping; fundus autofluorescence and fluorescein/indocyanine green angiography support selected cases. Laboratory tests do not diagnose AMD, but metformin exposure, renal function, and diabetes control still matter for holistic counselling and vascular risk—do not anchor AMD guidance to non-eye labs.

Referral targets: any suspected wet change is urgent; intermediate dry AMD should be risk-stratified (disease in second eye, hypertension, smoking) with the interval adjusted downward.

1. Stabilise context: record monocular symptoms, time course, last ophthalmology review, anti-VEGF schedule, and steroid/glaucoma history.
2. Risk screen: smoking status, BP, diabetes, anti-thrombotic use—informs counselling and peri-injection planning per local policy.
3. Stratify phenotype: dry only versus exudative; if any central distortion—expedite imaging today.
4. Activate treatment path: wet AMD—ophthalmology intravitreal pathway; dry intermediate—AREDS2 discussion and monitoring cadence; GA—low-vision and mobility safeguards.
5. Safety-net: teach red-flag symptoms; ensure transport for injection days; document discussions on driving where central vision fails licensing thresholds.
6. Evaluate response: fewer injections on treat-and-extend still requires interval stability on OCT—non-attendance is a top reason for avoidable outcome loss.

• Diabetic macular oedema versus AMD—OCT distinguishes cystoid intraretinal fluid patterns; many older adults have both.
• Epiretinal membrane / macular hole—distortion without drusen cluster; OCT confirms.
• Retinal vein occlusion—sectoral haemorrhage, cotton wool spots; history of hypertension.
• Acute posterior multifocal placoid pigment epitheliopathy or serpiginous choroiditis—inflammatory signs; often younger—refer for uveitis work-up.
• Non-arteritic ischaemic optic neuropathy—afferent pupillary defect, altitudinal field defects—different emergency.

Neovascular AMD

First-line therapy is intravitreal anti-VEGF. Agents in common use include ranibizumab, aflibercept, and bevacizumab (off-label in many systems); newer agents (e.g. brolucizumab, faricimab) appear per formulary with agent-specific safety monitoring. Treat-and-extend after a loading phase reduces visit burden when disease stays dry on OCT—extension stops if fluid recurs.

Photodynamic therapy and thermal laser are niche after the anti-VEGF era; occasional regimens still combine modalities per retina specialist.

Dry intermediate AMD

AREDS2 formulation (vitamin C, vitamin E, zinc, copper, lutein, zeaxanthin—without beta-carotene) can slow progression to late AMD in selected patients with bilateral intermediate disease or late AMD in one eye—confirm eligibility with ophthalmology rather than starting ad hoc multivitamins.

Geographic atrophy

Complement inhibitors (e.g. pegcetacoplan, avacincaptad) are emerging in some jurisdictions with infection-safety and injection-burden trade-offs—follow regional prescribing summaries.

Nursing supports

Use eye-care teaching for lid hygiene pre-injection, drop instillation after dilatation, and handoff documentation of visual acuity. Medication literacy around drops (steroid, antibiotic) reduces microbial resistance and corneal toxicity.

• Injection-day workflow: verify correct eye marked, allergies, INR/anticoagulation per local protocol, post-vitals if sedation/anxiety, and aftercare antibiotics only if prescribed.
• Monitoring intervals: dry intermediate—typically 6–12 months; wet active—often monthly until loading complete then extend per OCT; missed visits warrant proactive recall.
• Drug safety: acute ocular inflammation signals with some agents require immediate reporting—keep condition-specific patient information leaflets current.
• Falls prevention: central vision loss increases edge-hazard missteps—refer occupational therapy when clutter, lighting, or contrast issues dominate.
• Mental health: acknowledge grief about reading loss; signpost low-vision rehabilitation early, not after legal blindness.

• Tractional or atrophic macular scar after chronic / recurrent exudation—limits recovery even when fluid clears.
• Endophthalmitis (rare but vision-threatening) post intravitreal injection.
• Sustained IOP elevation or steroid-response glaucoma when adjunct steroid drops are used—align with glaucoma team.
• Bilateral involvement erodes independence; watch nutrition (food preparation), medication errors, and depression.
• Anti-VEGF systemic exposure is usually low but document cerebrovascular events when pharmacovigilance forms are indicated.

Progression risk drops when smoking stops, blood pressure targets are met, and glycaemia improves—interventions that also protect diabetic eye disease. Encourage outdoor sun protection and dietary patterns consistent with cardiovascular health. AREDS2 remains selective—avoid promoting supplements in early dry AMD without specialist indication.

Wet AMD outcomes hinge on time-to-treatment and persistence: early anti-VEGF when fluid is present preserves more photoreceptors than delayed rescue. Dry AMD may remain stable for years or advance insidiously—fellow-eye risk rises once one eye hits late stage. Honest counselling pairs realistic central vision expectations with empowered low-vision strategies.

Ward nurses rarely “cure” AMD but frequently protect vision by catching referrals, ensuring transport, translating jargon-free follow-up plans, and flagging infection. People may hide functional loss—ask practical questions about insulin pen dial readability, insulin dosing verification, and meal preparation.

• Document monocular acuity in handover when a therapy could affect perfusion or sedation depth.
• After dilated examinations, verify mobility support to prevent falls.
• Pair ophthalmology instructions with written schedules—many patients juggle multiple injection cadences.

Nursing-priority lens (NCSBN Clinical Judgment Measurement Model): recognise cues → analyse cues → prioritise hypotheses → generate solutions → take safe action → evaluate outcomes. These NCLEX-style clinical judgment practice items use unfolding case, SATA, triage, ordered response, matrix matching, and cloze formats around AMD recognition, anti-VEGF safety, OCT-informed monitoring, and supplement stewardship.